Celldex Therapeutics shares surge as lead asset shows promise in skin conditions

Norge Nyheter Nyheter

Celldex Therapeutics shares surge as lead asset shows promise in skin conditions
Norge Siste Nytt,Norge Overskrifter
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 53 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 97%

Experimental treatment proves effective in treating hives and an inflammatory skin disease

Celldex Therapeutics CLDX, +8.20% shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset in both chronic hives and an inflammatory skin disease.

The treatment, a monoclonal antibody called barzolvolimab, produced clinically meaningful responses in patients with moderate to severe chronic spontaneous urticaria, which is characterized by hives that last six weeks or longer and have no identifiable causes, Celldex said in a release Monday. Data from more than 200 patients showed that barzolvolimab achieved the study’s primary goal, which was a statistically significant change in hives activity after 12 weeks, compared with a placebo, the biotech company said.

Separately, Celldex on Sunday released promising early-stage results from a trial of barzolvolimab in prurigo nodularis, a chronic skin disorder that causes an itchy rash. Celldex is looking to start a phase 2 study of the treatment in prurigo nodularis early next year, president and CEO Anthony Marucci said in a statement.

The early efficacy data are “highly encouraging” and support the thesis that the treatment could be a best-in-class therapy, Leerink Partners analysts said in a note Sunday.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

MarketWatch /  🏆 3. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 eachCargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 eachCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Les mer »

Treat Your Parched Skin To These 39 Hydrating ProductsTreat Your Parched Skin To These 39 Hydrating ProductsThese things will give your skin that 'ahhh, refreshing' feel.
Les mer »

The Watchdog Nation Electricity Club is where Texans share electricity woes and winsThe Watchdog Nation Electricity Club is where Texans share electricity woes and winsFrom solar power to PowerToChoose.org, Texans have strong ideas about their electricity service
Les mer »

Hudson County communities share nearly $9 million in state aid for road improvementsHudson County communities share nearly $9 million in state aid for road improvementsMore than 40% of the funding, $66.7 million, is going to 173 municipalities with Complete Streets policies.
Les mer »

‘I pray with them’: Pro-Palestinian college activists share message for families of kidnapped Israelis‘I pray with them’: Pro-Palestinian college activists share message for families of kidnapped IsraelisAmerican University students that participated in a walkout event in support of Palestinians in Gaza and the West Bank said they sympathize with the families of Israeli hostages.
Les mer »



Render Time: 2025-02-27 20:43:47